Samsung Bioepis Receives the US FDA's Approval for Multi-Dose Vial of Ontruzant (biosimilar- trastuzumab)
Shots:
- The US FDA has approved the 420 mg multi-dose vial of Ontruzant (trastuzumab-dttb)- a biosimilar referencing Herceptin (trastuzumab) and will be marketed & distributed by Merck in the US
- On Feb 05- 2020- Merck has announced the spin-off its biosimilar business and will continue to support the commercialization of Ontruzant until the spinoff- which is anticipated to be held in H1’21
- Ontruzant (150 mg- single-dose vial) is an approved therapy for HER2-overexpressing BC- mBC and mGC or gastroesophageal junction adenocarcinoma in patients with prior treatment for metastatic disease
Click here to read full press release/ article
Ref: Samsung Bioepis | Image: Samsung Bioepis
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com